LISATA THERAPEUTICS, INC. — Director's Dealing 2017

May 22, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Caladrius Biosciences, Inc. (CLBS)
CIK: 0000320017
Period of Report: 2017-05-18

Reporting Person: Talamo Joseph (SVP and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-05-18	Common Stock	F	5982	$5.13	Disposed	15619	Direct